Oral bisphosphonates for paediatric osteogenesis imperfecta?

The Lancet

Volumn 382, Issue 9902, 2013, Pages 1388-1389

  Ward, Leanne M ^a   Rauch, Frank ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; RISEDRONIC ACID;

ADVERSE OUTCOME; BONE DEFORMATION; BONE DENSITY; BONE TURNOVER; DISEASE SEVERITY; DRUG SAFETY; FEMUR; FINGER FRACTURE; FRACTURE; HIGH RISK BEHAVIOR; HUMAN; LEG FRACTURE; LUMBAR SPINE; MORBIDITY; NOTE; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; SPINE; SPINE FRACTURE; TIBIA FRACTURE; TREATMENT OUTCOME;

EID: 84886291379     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61531-7     Document Type: Note

References (13)

1. Ben Amor IM, Roughley P, Glorieux FH, Rauch F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsuffi ciency mutations in COL1A1. J Bone Miner Res 2013; published online March 25. DOI:10.1002/jbmr.1942.
2. Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 2010; 6: 367-81.
3. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011; 7: 540-57.
4. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-52.
5. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: 758-63.
6. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293-99.
7. Shapiro JR, McCarthy EF, Rossiter K, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 2003; 72: 103-12.
8. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005; 90: 4051-56.
9. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004; 363: 1427-31.
10. Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25: 786-91.
11. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 2009; 24: 1282-89.
12. Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 2011; 96: 355-64.
13. Bishop N, Adami S, Ahmed SF, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 2013; published online Aug 8. http://dx.doi.org/10.1016/S0140-6736(13) 61091-0.